Silverback Therapeutics is a privately held biotechnology company advancing a pipeline of first-in-class therapies targeting fundamental disease pathways that are systemically delivered but locally active. Enabled by the company's proprietary ImmunoTAC platform, Silverback's pipeline is rapidly advancing towards clinical studies in several therapeutic areas, including oncology and fibrosis. Since its inception in 2016, Silverback has raised $47.5 million in venture capital financing from OrbiMed, Celgene Corporation and Alexandria Venture Investments.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/19/18 | $47,500,000 | Series A |
Alexandria Real Estate Equities Celgene Corporation OrbiMed Advisors  | undisclosed |
| 03/11/20 | $78,500,000 | Series B |
Alexandria Venture Investments Bristol-Myers Squibb Colt Ventures Hunt Investment Group Nextech Invest NS Investment OrbiMed Advisors Pontifax US Venture Partners | undisclosed |
| 09/23/20 | $85,000,000 | Series C |
Boxer Capital EcoR1 Capital Fidelity Management & Research Company Hunt Technology Ventures Nantahala Capital Nextech Invest OrbiMed Advisors Pontifax RA Capital Management US Venture Partners | undisclosed |
